Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Express Scripts
US Army
Covington
Deloitte
US Department of Justice
Farmers Insurance
Fish and Richardson
Cipla

Generated: June 25, 2018

DrugPatentWatch Database Preview

SUPRAX Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Suprax patents expire, and when can generic versions of Suprax launch?

Suprax is a drug marketed by Lupin Ltd, Lederle, and Lupin Pharms. and is included in eight NDAs. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has two patent family members in two countries.

The generic ingredient in SUPRAX is cefixime. There are fourteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the cefixime profile page.
Summary for SUPRAX
Drug patent expirations by year for SUPRAX
Pharmacology for SUPRAX
Medical Subject Heading (MeSH) Categories for SUPRAX
Synonyms for SUPRAX
(-)-Cefixim
(6R,7R)-7-((Z)-2-(2-Aminothiazol-4-yl)-2-((carboxymethoxy)imino)acetamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl}amino)-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-(carboxymethyl)oxime) trihydrate
(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-(carboxymethyl)oxime)trihydrate
(6r,7r)-7-[-2-(2-amino-thiazol-4-yl)-2-carboxymethoxyimino-acetylamino]-8-oxo-3-vinyl-5-thia-1-aza-b
(6R,7R)-7-[-2-(2-Amino-thiazol-4-yl)-2-carboxymethoxyimino-acetylamino]-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4. 2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethyloxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-[[(2Z)-2-(2-Amino-4-thiazolyl)-2-[(carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
(6R,7R)-7-[[(2z)-2-(2-amino-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]Oct-2-ene-2-carboxylic acid
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(carboxymethyl)oxy]imino}acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
214265-67-5
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)((carboxymethoxy)imino)acetyl)amino)-3-ethenyl-8-oxo-, trihydrate, (6R-(6alpha,7beta(Z)))-
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2Z)-(2-amino-4-thiazolyl)((carboxymethoxy)imino)acetyl)amino)-3-ethenyl-8-oxo-, (6R,7R)-
50C371
79350-37-1
7beta-{(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido}-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid
AB00513842
AB0073052
AC-4350
AC1NSFNI
AK326220
AKOS015854940
AKOS015961135
AT-7061
BC205782
BDBM84007
BPBio1_000622
BRD-K71059170-001-02-5
BRN 6025058
BSPBio_000564
C04
C06881
CCG-220462
Cefixim
Cefixima
Cefixima [Spanish]
CEFIXIME
Cefixime (JAN/USP/INN)
Cefixime (JP15/USP/INN)
Cefixime [USAN:USP:INN:BAN:JAN]
Cefixime Anhydrous
Cefixime EP Impurity C (Cefixime 7-epimer)
Cefixime, Antibiotic for Culture Media Use Only
Cefixime(7-[[(2-amino-4-thiazolgl)(Carboxymethoxg)imino]acetyl]amino-3-vinyl -8-oxo-5-thia-1-azabicyclo[4,2,0]oct-2-ene-2-Carboxylicacidtrihydrate)
cefiximine
Cefiximum
Cefiximum [Latin]
Cefixoral
Cefspan
Cephoral
CFIX
CHEBI:472657
CHEMBL1541
cid_5362065
CL 284,635
CL-284635
CS-4820
D00258
D06OVY
DB00671
Denvar
FK-027
FR- 17027
FR-17027
HE325243
HMS2096M06
HMS2234J21
HY-B1381
LS-187248
MFCD00865020
MLS002222332
MolPort-003-845-687
NCGC00179521-01
Necopen
Ofex (TN)
Prestwick3_000462
PubChem13762
RS0002
s4596
SCHEMBL24945
SMR001307271
Suprax (TN)
TC-070894
Tricef
UNII-XZ7BG04GJX
Unixime
X-2622
XZ7BG04GJX
ZINC12503147

US Patents and Regulatory Information for SUPRAX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin Ltd SUPRAX cefixime CAPSULE;ORAL 203195-001 Jun 1, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Lupin Ltd SUPRAX cefixime TABLET, CHEWABLE;ORAL 065380-002 Oct 25, 2010 RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Lupin Pharms SUPRAX cefixime FOR SUSPENSION;ORAL 065129-001 Feb 23, 2004 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Lupin Ltd SUPRAX cefixime TABLET, CHEWABLE;ORAL 065380-003 Oct 25, 2010 RX No Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for SUPRAX
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe for Oral Suspension 500 mg/5 mL ➤ Subscribe 2014-07-22

Non-Orange Book US Patents for SUPRAX

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,241,905 Pharmaceutical compositions of Cefixime ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Daiichi Sankyo
Cipla
Boehringer Ingelheim
Dow
Harvard Business School
US Army
Chubb
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.